ArticleBMC cancer2025

Trajectories of α-fetoprotein and unresectable hepatocellular carcinoma outcomes receiving lenvatinib: a retrospective, multicenter cohort study.

Yitao Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.